New insider activity at Cognition Therapeutics ( (CGTX) ) has taken place on February 5, 2025.
Director Lisa Ricciardi has made a significant investment in Cognition Therapeutics by purchasing 38,851 shares, totaling an investment of $29,915.
Recent Updates on CGTX stock
Cognition Therapeutics has reported promising results from their Phase 2 SHIMMER study, showcasing the efficacy and safety of zervimesine in treating dementia with Lewy bodies (DLB). The study demonstrated significant improvements in behavioral, functional, cognitive, and movement measures. These results have positioned zervimesine as a potential first-to-market treatment for DLB, supported by strong intellectual property and a favorable safety profile. Consequently, analysts have upgraded their view of the stock, reflecting increased confidence in the company’s future prospects.
More about Cognition Therapeutics
YTD Price Performance: -7.50%
Average Trading Volume: 7,743,250
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $27.67M
Questions or Comments about the article? Write to editor@tipranks.com